Methamphetamine (Meth) abuse not only increases the risk of human immunodeficiency virus-1 (HIV-1) infection, but exacerbates HIV-1-associated neurocognitive disorders (HAND) as well. The mechanisms underlying the co-morbid effect are not fully understood. Meth and HIV-1 each alone interacts with microglia and microglia express voltage-gated potassium (K V ) channel K V 1.3. To understand whether K V 1.3 functions an intersecting point for Meth and HIV-1, we studied the augment effect of Meth on HIV-1 glycoprotein 120 (gp120)-induced neurotoxic activity in cultured rat microglial cells. While Meth and gp120 each alone at low (subtoxic) concentrations failed to trigger microglial neurotoxic activity, Meth potentiated gp120-induced microglial neurotoxicity when applied in combination. Meth enhances gp120 effect on microglia by enhancing microglial K V 1.3 protein expression and K V 1.3 current, leading to an increase of neurotoxin production and resultant neuronal injury. Pretreatment of microglia with a specific K V 1.3 antagonist 5-(4-Phenoxybutoxy)psoralen (PAP) or a broad spectrum K V channel blocker 4-aminopyridine (4-AP) significantly attenuated Meth/gp120-treated microglial production of neurotoxins and resultant neuronal injury, indicating an involvement of K V 1.3 in Meth/gp120-induced microglial neurotoxic activity. Meth/gp120 activated caspase-3 and increased caspase-3/7 activity in microglia and inhibition of caspase-3 by its specific inhibitor significantly decreased microglial production of TNF-α and iNOS and attenuated microglia-associated neurotoxic activity. Moreover, blockage of K V 1.3 by specific blockers attenuated Meth/gp120 enhancement of caspase-3/7 activity. Taking together, these results suggest an involvement of microglial K V 1.3 in the mediation of Meth/gp120 co-morbid effect on microglial neurotoxic activity via caspase-3 signaling.
Introduction
Methamphetamine (Meth) abuse and human immunodeficiency virus (HIV) type 1 (HIV-1) infection are two major public health problems worldwide. Meth abuse not only increases the risk of HV-1 infection but potentiates HIV-1-associated neurotoxicity as well (Theodore et al., 2007; Theodore et al., 2006; Urbina and Jones, 2004) . While a large body of research has investigated the individual effects on the brain, far less has focused on their synergistic influence. Increasing evidence indicates that Meth and HIV-1 appear to produce more severe neuropathology and neurocognitive deficits than each alone (Hoefer et al., 2015; Rippeth et al., 2004; Silverstein et al., 2011) . Nevertheless, the mechanisms underlying the co-morbid effect of Meth and HIV-1 are not fully understood. Studies have shown that HIV-1 brain infection causes microglia (brain microglia and macrophages) activation and release of pro-inflammatory molecules leading to the development of HIV-1-associated neurocognitive disorders (HAND) (Gannon et al., 2011; Garvey et al., 2014; Kaul and Lipton, 2006a; Letendre, 2011) . Meth abuse exacerbates HAND (Carey et al., 2006; Chana et al., 2006; Kesby et al., 2015b; Silverstein et al., 2012) , and such an exacerbation is also associated with microglial neurotoxic activity (Cadet and Krasnova, 2007; Hauser and Knapp, 2014; Silverstein et al., 2011) . Thus, microglia appears to be a common target for both Meth and HIV-1.
Microglia, the resident immune competent phagocytic cells in the brain, is the predominant cell type productively infected by HIV-1 (Lipton and Gendelman, 1995) . A striking feature in an HIV-1-infected brain is microglial activation, and the activated microglia exhibits neurotoxic activity by releasing a variety of neurotoxic substances leading to neuronal injury and ultimate development of HAND. Multiple lines of evidence have also shown a robust activation of microglia following exposure of rodents to a neurotoxic regimen of Meth (Kuhn et al., 2008; LaVoie et al., 2004; Loftis and Janowsky, 2014) . Meth acts on microglia and alters microglial activity and inflammatory signaling cascades, resulting in neuronal damage (Loftis and Janowsky, 2014; Silverstein et al., 2012) . How Meth abuse potentiates HIV-1-associated microglial neurotoxic activity remains unclear. Molecular and Cellular Neuroscience 82 (2017) [167] [168] [169] [170] [171] [172] [173] [174] [175] It has been shown that microglia express several types of voltagegated potassium (K V ) channels including inward rectifier K ir 2.1 and outward rectifiers K V 1.5 and K V 1.3. Exposure to a variety of stimuli produces a characteristic pattern of up-regulation of K V 1.3 (Eder, 1998; Fischer et al., 1995; Norenberg et al., 1994; Schilling et al., 2000) . Accumulating evidence indicates that microglial K V 1.3 plays an important role in switching microglia from a resting condition to an activation state (Farber and Kettenmann, 2005; Kotecha and Schlichter, 1999) . Electrophysiological studies have revealed the presence of large outward rectifying K currents that has been speculated as a sign of microglia activation (Ilschner et al., 1996; Visentin et al., 1995; Visentin and Levi, 1997; Visentin et al., 2001) . Activated microglia produces soluble pro-inflammatory molecules resulting in neuronal injury via a process requiring K V 1.3 activity since blockage of microglial K V 1.3 or decrease of K V 1.3 expression attenuates microglia-mediated neurotoxicity (Fordyce et al., 2005; Nutile-McMenemy et al., 2007) . We hypothesize that Meth potentiates HIV-1-associated microglial neurotoxic activity via activation of K V 1.3. To test our hypothesis, we studied the co-morbid effects of Meth on HIV-1 envelope glycoprotein 120 (gp120)-associated microglial neurotoxic activity on primary rat neural cell cultures. Our results showed that application of Meth or gp120 each alone at a low concentration had no apparent effect on triggering microglial neurotoxic activity. When applied in combination, however, Meth significantly potentiated gp120-induced microglial neurotoxicity. The Meth potentiation of gp120-associated microglial neurotoxic activity was blocked by specific K V 1.3 channel blockers, suggesting an involvement of K V 1.3 in Meth-mediated potentiation.
Materials and methods

Materials
HIV-1gp120 MN (product #1021-2) was purchased from Immunodiagnostics, Inc. (Woburn, MA). Aliquots of gp120 were kept as 100 nM stock solution at −80°C. The stock solution was diluted to desired concentrations with artificial cerebrospinal fluid (ACSF) 2-5 min before test. (+)methamphetamine was purchased from Sigma (St. Louis, MO, Cat # M-8750) with DEA license # RX0374974. All chemicals, unless otherwise specified, were from Sigma.
Animals
Pregnant female Sprague-Dawley rats used for experiments were purchased from Charles River Laboratories (Wilmington, MA). Animals were housed at constant temperature (22°C) and relative humidity (50%) under a regular light-dark cycle (light on at 7:00 AM and off at 5:00 PM) with free access to food and water. All animal use procedures were strictly reviewed by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center (IACUC No. 13-069-10-EP).
Isolation and culture of microglial and neuronal cells
Microglia and neurons were prepared from the cerebral cortex of postnatal 0-1 day old or 18-day old embryonic Sprague Dawley rats as described previously (Liu et al., 2012) . In brief, rat cortical tissues were dissected in cold Hank's Balanced Salt Solution (HBSS: Mediatech, Inc. Manassas, VA) and digested with 0.25% trypsin and 200 kunitz units/ml DNase (Sigma-Aldrich, St. Louis. MO) in 37°C for 15 min. The digested tissues were then suspended in cold HBSS and filtrated through 100 μM and 40 μm pore cellular strainers (BD Bioscience, Durham, NC), respectively. For microglial culture, the isolated cells (25 × 10 6 ) were plated into T75 cm 2 flasks in a high-glucose Dulbecco's modified Eagle's medium (DMEM) contained 10% fetal bovine serum (FBS), 1 × glutaMAX, 1% penicillin/streptomycin (Life Technologies, Grand Island, NY), and 300 ng/ml macrophage colony- /well) based on the experimental requirements with M-CSF free DMEM. The suspensory glial cells were removed 1 h after seeding by changing culture media. The resultant cultures were 98-100% microglia as determined by staining with anti-Iba1 (Wako, Richmond, VA), a marker for microglia. For neuronal culture, the isolated cells were seeded in poly-D-lysine-coated plates at a density of 0.05x10 6 cells/well in 96-well plates, 0.2 × 10 6 cells/well in 12-well plates, or 1.0 × 10 6 cells/well in 6-well plates. Neuronal cultures were maintained at 37°C for 10 days in neurobasal medium supplemented with 2% B27, 1% penicillin/streptomycin and 0.25% glutaMAX (all regeants from Life Technologies). The purity of neuronal cells (N90%) was determined by staining with microtubule-associated protein-2 antibody (MAP-2: 1:1000, Chemicon, Temecula, CA).
Collection of microglial conditioned media
After detachment from flasks, microglial cells were placed in 6 well plates and cultured for 48 h and then treated with Meth or gp120 or both for additional 24 h. After washing three times with PBS, the cells were added with fresh neurobasal media and cultured for another 24 h. The culture supernatants (free of Meth and gp120) were then collected and stored at −80°C freezer for subsequent experimental use.
Electrophysiology
Whole-cell outward K + currents were recorded from primary rat microglial cultures at room temperature. Pre-treated microglia were perfused with oxygenated (bubbled with 95% O 2 , 5% CO 2 ) artificial cerebrospinal fluid (ACSF) containing (in mM) NaCl 150, KCl 4.5, CaCl 2 2, MgCl 2 1, HEPES 5, glucose 11, pH 7.3 (adjusted with NaOH) with an osmolarity of 310 mOsm. Patch-clamp electrodes, pulled from borosilicate glass capillaries (WPI, Sarasota, FL) had tip resistance of 4-6 Ω when filled with pipette solution containing (mM): KCl 150, MgCl 2 , CaCl 2 1, EGTA 11, HEPES 10, with pH of 7.3 adjusted with KOH. Voltage-dependent currents were evoked by voltage steps (600 ms in duration) with the first step from a holding potential of -70 mV to − 150 mV and then to +70 mV in a 20 mV increments. The seal resistance was 1-10 GΩ. Junction potentials were corrected, and the cell capacitance was compensated (~70%) in most cells. Current signals were amplified with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA). The current and voltage traces were displayed and recorded in a Dell computer using pClamp 10.1 data acquisition/analysis system. The outward K + current density (pA/pF) was calculated by dividing the cell capacitance from the peak current generated by a voltage step.
Measurement of Nitric Oxide (NO) and Reactive Oxygen Species (ROS) productions
NO production was estimated by measuring the concentration of nitrite with Griess Reagent System according to the manufacturer's instructions (Promega, Madison, WI). Supernatants (50 μl) collected from pre-treated microglia were mixed with equal volume of the sulfanilamide solution for 10 min followed by 50 μl of NED solution and continued incubation for 10 min at room temperature. The optical density of reactants was measured at 520 nm and 540 nm using an ELISA plate reader. All experiments were repeated at least three times. For analysis of ROS production, 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA) kit was used (Life Technologies). Pretreated microglia was cultured with 2 μM of CM-H 2 DCFDA for 1 h at 37°C. Afterwards, microglia were mounted with ProLong Gold antifade reagent with 4′,6′-diamidino-2-phenylindol (DAPI) staining nuclei (Life Technologies) and visualized by Nikon fluorescent microscope in a 40× objective.
TUNEL staining and MTT assay
Neuronal damage was evaluated using In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science, Indianapolis, IN). In brief, neurons growing on poly-D-lysine-coated coverslips (0.2 × 10 6 cells/well in a 12-well plate) were treated with conditional media collected from pre-treated microglia at 1 ∶ 5 dilution for 24 h. Afterwards, neurons were fixed with 4% paraformaldehyde, followed by permeabilizing with 0.1% Triton X-100. The neurons were then processed for TUNEL staining (green) for 1 h at 37°C and mounted with ProLong Gold antifade reagent with DAPI (Life Technologies). Cells were visualized by Nikon fluorescent microscope in a 40× objective. The percentage of damaged neurons was determined by TUNEL positive cells normalized by total cells. Neuronal damage was also assessed by MTT assay and a reduction of MTT colorimetry was considered as an indicator of cell damage or death. Pre-treated neurons were exposed to fresh neurobasal medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (500 μg/ml) for 3 h. MTT solution was then replaced with 300 μl of dimethyl sphingosine (DMSO, SigmaAldrich) for cell lyses, and the optical density (OD) of absorption was measured at 560 nm.
Western blot analysis
Membrane proteins were prepared using a Membrane Protein Extraction Kit (BioVision, Mountain View, CA) according to manufacturer's instructions. Total proteins were isolated using a RIPA Buffer (Sigma-Aldrich). Twenty microgram membrane proteins or 30 μg total proteins were separated by electrophoresis using 4-15% mini-protean TGX precast gel and transferred to polyvinyl difluoride (PVDF) membranes. Membranes were blocked with 5% dry milk in tris-buffered saline (TBS) (all products from Bio-Rad Laboratories, Hercules, CA) and probed overnight at 4°C with primary -antibodies including rabbit polyclonal K V 1.3 (1:100; Alomone Lab, Israel), anti-iNOS, anti-TNF-α, anti-IL-1β antibody (1:100, Abcam, Cambridge, MA), cleaved caspase-3 antibody, caspase-3 rabbit mAb (1:1000; Cell Signaling Technology, Danvers, MA), and anti-mouse β-actin monoclonal antibody (1:10,000, SigmaAldrich). Membranes were washed (4 times, 10 min each) in TBS with 0.2% Tween (TBS-T) and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit, or anti-mouse secondary antibody (1:10,000, Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h at RT. Labeled proteins were visualized by Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL). Band densities of K V 1.3, iNOS, TNF-α, IL-1β were normalized to their β-actin, and cleaved caspase-3 was normalized to caspase-3 in each sample.
Caspase-3/7activity assay
Caspase-3/7 activity was evaluated by Caspase-Glo 3/7 assay kit (Promega). In brief, control and pre-treated microglia in a white-walled 96-well luminometer plate were exposed to equal volume of enzyme or vehicle and incubated to equilibrium. After 30 min, 100 μl of CaspaseGlo 3/7 reagents were added to each well and gently mixed. Cells were then continuously incubated at room temperature for 6 h or 24 h. The luminescent activity of Caspase-Glo 3/7 was read in a platereading luminometer (BioTek Instruments, Inc., Winooski, VT).
Statistical analysis
Experimental data were expressed as mean ± S.D. unless otherwise indicated. Statistical analyses were performed on SAS® 9.4 using general linear model methods, especially (nested) ANOVA (two-way, threeway or four-way according to the structure of the data) followed by Dunnett's test for comparing one treatment with the rest (Littell et al., 2002) . The difference between groups was considered significant when p b 0.05.
Results
Meth enhances gp120-induced microglial neurotoxic activity
Ample evidence indicate that HIV-1-infected and immune-activated microglia release soluble, neurotoxic molecules leading to the pathogenesis of HAND. The incidence and severity of HAND are increased with concomitant use of Meth, suggesting that Meth may potentiate HIV-induced microglial neurotoxicity. To determine whether Meth potentiates HIV-associated microglial neurotoxic activity, we first collected the supernatants recovered from cultured rat microglia treated with gp120 or Meth at different concentrations, and then tested their effects on cultured rat cortical neurons via MTT assay. As analyzed by twoway ANOVA (gp120, F 3,28 = 24.24, p b 0.001; Meth, F 3,28 = 425.20, p b 0.001) and shown in Fig. 1A , addition of gp120 (0.1, 0.5, 1.5 nM)-or Meth (2, 20, 200 μM)-treated microglial supernatants (1:5 dilution, v/v) each alone to the neuronal cultures for 24 h produced a concentration-dependent decrease of the percentage of surviving neurons (as indicated by MTT reduction) to 95.21 ± 3.93% (p ≥ 0.05, Dunnett's test, the same in the following), 89.54 ± 5.50% (p b 0.05) and 78.70 ± 8.61%(p b 0.01), or to 95.07 ± 8.99% (p ≥ 0.05), 94.25 ± 3.29% (p ≥ 0.05), and 78.13 ± 5.04% (p b 0.01) of control (untreated), respectively. As gp120 0.1 nM and Meth 20 μM had no significant effects on neuronal viability when applied alone, we examined if Meth 20 μM could potentiate gp120 (0.1 nM) effect of microglial neurotoxic activity. Also shown in Fig. 1A (far right), the supernatants recovered from microglia treated with Meth (20 μM) and gp120 (0.1 nM) in combination significantly decreased the percentage of surviving neurons (p b 0.001), suggesting Meth potentiation of gp120-induced microglial neurotoxic activity. As Meth (20 μM) and gp120 (0.1 nM) in combination significantly decreased neuronal survival, this combination was used for subsequent experiments.
Meth potentiation of gp120 on microglial neurotoxic activity was further examined by TUNEL staining. After addition of the conditioned media recovered from Meth (20 μM)-, gp120 (0.1 nM)-, or Meth + gp120 (Meth/gp120)-treated microglia to the neuronal cultures for 24 h, the TUNEL positive cells were 12.5 ± 3.82%, 11.99 ± 3.42%, or 30.56 ± 6.86%, respectively ( Fig. 1B and C) . To determine if K channel K V 1.3 is involved in Meth potentiation of gp120 neurotoxicity, we tested effects of 4-aminopyridine (4-AP), a broad-spectrum blocker of members of K V 1 channel family, and PAP, the specific K V 1.3 channel blocker, on their blockage of Meth/gp120-mediated neurotoxicity. As shown in Increasing evidence indicates that microglial K channel K V 1.3 plays an important role in microglial activation (Farber and Kettenmann, 2005; Kotecha and Schlichter, 1999) , and activated microglia release neurotoxic molecules leading to neuronal injury. We previously showed that HIV-1 gp120 enhanced K V 1.3 current recorded in cultured rat microglia (Liu et al., 2012) . We hypothesize that Meth may potentiate gp120-associated neurotoxicity by augmenting gp120 enhancement of the microglial K V 1.3 current. To address this hypothesis, we tested the effect of Meth and gp120 on microglial whole-cell current alone or together. As shown in Fig. 2A and B, when microglia were incubated with Meth (20 μM) or gp120 (0.1 nM) alone for 2 h, there was no significant changes in outward K currents although gp120 showed a decrease of inward currents (statistically not significant). However, the outward K current was significantly increased when Meth and gp120 were added together to microglial culture media, suggesting that Meth potentiates gp120 enhancement on microglial outward K current. To understand if the Meth/gp120-induced increase of outward K current was associated with elevated expression of K V 1.3 protein in microglia, we detected the levels of microglial K V 1.3 protein expression by Western blot analyses. Microglia treated with Meth (20 μM) or gp120 (0.1 nM) alone for 24 h exhibited no significant change on the levels of K V 1.3 protein expression with 1.06 ± 0.009 fold of control (Meth) or 0.96 ± 0.008 fold of control (gp120), respectively (Fig. 2C) . In contrast, the levels of K V 1.3 protein expression increased to 1.45 ± 0.03 fold of control with the addition of Meth and gp120 together. The difference was statistically significant (p b 0.01), suggesting a potential mechanism underlying Meth augmentation of gp120 enhancement of microglial outward K current.
Meth augments gp120 increase of neurotoxin expression levels in microglia
HIV-1-infected and immune activated macrophages and microglia produce pro-inflammatory molecules including cytokines and NO leading to neuronal dysfunction and injury. After demonstration of Meth potentiation of gp120-induced microglial neurotoxicity via K V 1.3, we further examined whether Meth augments gp120-associated increase of neurotoxin expression levels in microglia. Western blot analyses showed that addition of Meth and gp120 each alone to microglial culture for 24 h slightly altered expression levels of IL-1β but not TNF-α. Compared with the levels detected from untreated microglia, the fold changes for IL-1β were 1.55 ± 0.42 (Meth) and 1.17 ± 0.28 (gp120), respectively ( Fig. 3A-C) . In contrast, addition of Meth and gp120 in combination (Meth/gp120) significantly increased the expression levels of both, with fold changes of 2.47 ± 0.86, for IL-1β and 2.82 ± 0.16 for TNF-α, respectively. The Meth/gp120-induced increase of cytokine expression was abrogated by PAP (10 nM) or 4-AP (0.5 μM). A four-way ANOVA showed that the fold changes mediated by four substances gp120 (F 1, 12 = 29.03, p b 0.001), Meth (F 1, 12 = 46.09, p b 0.001), 4-AP (F 1, 12 = 24.09, p b 0.001) and PAP (F 1, 12 = 28.97, p b 0.001) are statistically significant, indicating a positive and significant interaction between gp120 and Meth significant (F 1, 12 = 9.89, p = 0.0084657) and an involvement of microglial K V 1.3 in Meth/gp120-associated elevation of cytokine expression in microglia. Treatment of microglia with PAP or 4-AP each alone had no significant effects on TNF-α (1.36 ± 0.41, n = 2; or 1.28 ± 0.33, n = 2) or IL-1β production (1.62 ± 0.64, n = 2 or 1.59 ± 0.47, n = 2). In addition to cytokine assays, we also evaluated effects of Meth and gp120 on oxidative stress including NO and ROS productions. The levels of NO in supernatants from microglia treated with Meth/ gp120 exhibited a significant increase (15.13 ± 2.70 nM) compared with microglia treated with gp120 (6.79 ± 0.59 nM) or Meth (6.38 ± 2.04 nM) each alone. Addition of K V channel blockers (PAP or 4-AP) before application of Meth/gp120 significantly reduced NO production (gp120 + Meth + PAP, F 1, 16 = 8.38, p b 0.05; gp120 + Meth + 4-AP, F 1, 16 = 7.79, p b 0.05). The average concentration was 9.04 ± 1.05 nM (PAP pre-treated group) or 8.08 ± 2.65 nM (4-AP pre-treated) (Fig. 3D) . Treatment of microglia with PAP or 4-AP alone had no significant effect on alteration NO production. Similarly, microglial production of ROS was also detected by CM-H 2 DCFDA (a ROS detection reagent) immunoreaction. As shown in Fig. 3E , microglia treated with Meth/gp120 largely enhanced ROS production when compared with microglia treated with gp120 or Meth alone. This enhancement was attenuated by K V channel blockers PAP or 4-AP. Collectively, these results strongly support a critical role for K V 1.3 in the expression and production of neurotoxins by Meth/gp120-treated microglia.
Meth/gp120-induced microglial neurotoxicity requires caspase-3 signaling
Caspase 3 and 7 are frequent downstream effectors of the caspase cascade and are activated in HAND (Garden et al., 2002) and other neurodegenerative disorders (Hartmann et al., 2000; Su et al., 2000) . Recently, Burguillos et al. reported a novel function of caspases in regulation of microglial activation and microglia-associated neurotoxicity (Burguillos et al., 2011) . They found that activation of caspase-8 and caspase-3/7 cause microglial activation and neuronal injury. To determine whether caspase-3 signaling is involved in Meth/gp120-associated microglial activation, we first exposed microglia to Meth and gp120 each alone or in a combination for 6 h or 24 h and caspase-3/7 activity in microglial cultures was assessed by Luminescent Assay (Promega). As shown in Fig. 4A , a significant increase of DEVDase activity was observed 6 h (F 1, 16 = 31.83, p = 0.001) and 24 h (F 1, 16 = 19.20, p b 0.001) after exposure to Meth/gp120. The detected DEVDase activity, primarily caspase 3/7 activity, was in a time dependent manner and reached as high as 2.11 ± 0.18-and 2.65 ± 0.19-fold of control at time points of 6 and 24 h. In contrast, the caspase-3/7 activities at the same two time points were 1.40 ± 0.13-and 1.52 ± 0.34-fold of control, or 1.17 ± 0.12-and 1.27 ± 0.11-fold of control when microglia were treated with gp120 or Meth alone. Since caspase-3/7 activity accounts for both of the caspase-3 and caspase-7 DEVDase activity, we used a specific caspase-3 inhibitor (Casp-3 IH) to confirm the role of caspase-3 in microglial activation. Competitive inhibition of DEVDase activity with Casp-3 IH (2 μM) significantly blocked Meth/gp120-induced increase of caspase-3/7 activity (four-way nested ANOVA, 6 h, F 1, 16 = 200.57, p b 0.001; 24 h, F 1, 16 = 88.21, p b 0.001), suggesting caspase-3 signaling was involved in Meth/gp120-induced microglial activation. This suggestion was further confirmed by Western blot analyses. In Fig. 4B , treatment of microglia with Meth/gp120 for 24 h activated caspase-3 and elevated the level of cleaved caspase-3 expression to 1.89-fold of control. The elevated level of cleaved caspase-3, however, was not mitigated by pre-treatment of microglia with 2 μM Casp-3 IH, suggesting that casp-3 IH could inhibit DEVDase activity, but not block Meth/gp120-induced caspase-3 cleavage. To examine if inhibition of caspase-3/7 activity could abrogate Meth/gp120-associated microglial neuronal toxicity, we added Casp-3 IH (2 μM) to microglial culture 1 h prior to addition of Meth/gp120. In presence of Casp-3 IH, Meth/ gp120 failed to induce microglial production of TNF-α and iNOS ( Fig. 4C and D) . Moreover, neuronal damage induced by culture supernatant collected from Meth/gp120-treated microglia in the presence of Casp-3 IH was significantly (A three-way ANOVA, F 1, 10 = 35.19, p b 0.001) reduced to 11.9 ± 4.3 in comparison to supernatant treated with Meth/gp120 in the absence of Casp-3 IH (25.8 ± 4.0) (Fig. 4E) . Taken together, these data suggested an involvement of caspase-3 signaling in Meth/gp120 triggered microglial neurotoxic activity. Although caspase-3 is known as a major executor to induce apoptosis, the Meth/ gp120-induced increase in caspase-3/7 activity did not result in microglial cell death within 24 h.
3.5. Involvement of K V 1.3 in Meth/gp120 increase of caspase-3 activity in microglia
After demonstration that Meth potentiates gp120 enhancement of K V 1.3 protein expression and K V 1.3 currents, resulting in microglial activation, subsequent production of neurotoxins and consequent neuronal damage which were associated with an increase of microglial caspase-3 activity, we further investigated the link between K V 1.3 channels and caspase cascade on Meth/gp120-induced microglial neurotoxic activity. Either the specific K V 1.3 blocker PAP or the broad spectrum K V channel blocker 4-AP was added to the microglial cultures 1 h prior to addition of Meth, gp120 alone or in combination. The Caspase-3/7 activity was measured at 6 and 24 h. While Meth and gp120 each alone had no significant effects on caspase-3/7 activity, Meth/gp120 did produce a significant increase of caspase-3/7 activity that was significantly attenuated by pre-treatment of microglia with K V channel blockers PAP or 4- Fig. 4 . Meth/gp120-induced neurotoxicity requires caspase-3 signaling. A. Caspase-3/7 activity was quantified by using caspase-3/7 activity kit (Promega, Madison USA) 6 h and 24 after experimental treatments as indicated. Note that Meth and gp120 each alone had minimal effects on caspase-3/7 activity, but they significantly increased caspase-3/7 activity when applied in combination. The Meth + gp120 increase of caspase-3/7 activity was inhibited by Casp-3 IH, demonstrating Meth + gp120 enhancement of microglial caspase-3/7 activity. B, C and D. Western blots illustrate expression of cleaved caspase-3 and its internal control caspase-3 (B), iNOS (C), TNF-α (D), and β-actin of microglia. AP (Fig. 5A) , indicating an involvement of K V 1.3 in Meth/gp120 increase of caspase-3 activity in microglia. Consistent with this effect, the complementary study of caspase-3 cleavage revealed a similar finding, that is, Meth/gp120 led to an increase of caspase-3 cleavage (Fig. 5B ). This enhancement of cleaved caspase-3 expression on microglial cells was largely inhibited by PAP and 4-AP (Fig. 5B , a four-way nested ANOVA, F 1, 12 = 15.96, p b 0.001 for PAP, F 1, 12 = 52.12, p b 0.001 for 4-AP), supporting the involvement of K V 1.3 in Meth/gp120 increase of caspase-3 activity in microglia.
Discussion
It is widely accepted that HIV-1 infection has become a chronic illness with very low levels of viral replication and chronic immune activation when successfully treated with combined anti-retroviral therapy (cART) (Gates and Cysique, 2016; Jaeger and Nath, 2012; Watkins and Treisman, 2015) . Despite this promising success, HAND remains prevalent in the HIV-1-infected population (Alfahad and Nath, 2013; Heaton et al., 2011; Simioni et al., 2010) . While the underlying mechanisms remain to be determined, several comorbidities have been identified as important risk factors including drug abuse, in particular the abuse of Meth. HIV-1 reproduces in microglia, the brain immune cells, causing brain inflammation and pathogenesis of HAND (Gannon et al., 2011; Kaul and Lipton, 2006b; Letendre et al., 2011; Silverstein et al., 2012) . Meth abuse exacerbates HAND (Carey et al., 2006; Chana et al., 2006; Chang et al., 2005; Sekine et al., 2008) , and such an exacerbation is also associated with microglial neurotoxic activity (Cadet and Krasnova, 2007; Flora et al., 2003; Nath, 2010; Sekine et al., 2008; Silverstein et al., 2011) . To understand how Meth exacerbates HAND via microglia, we investigated Meth potentiation of gp120-induced microglial neurotoxic activity using sub-toxic concentrations of Meth and gp120 that were determined from dose-response studies (Fig. 1A) . We also examined involvement of a microglial K channel K V 1.3 in Meth-and gp120-associated microglial neurotoxic activity. We found that neither Meth (20 μM) nor gp120 (0.1 nM) had, when applied each alone, significant effect on inducing microglial neurotoxic activity as determined by analyzing neuronal survival rate after addition of the culture supernatants recovered from Meth-or gp120-treated microglia to the neuronal cultures, respectively. In contrast, the supernatant collected from cultured microglia treated with Meth and gp120 in combination significantly reduced neuronal survival rate, suggesting a synergistic effect of Meth and gp120 or Meth potentiation of gp120 effect on microglial neurotoxic activity. Such synergy/potentiation was associated in parallel with Meth/gp120-induced increase of K V 1.3 expression and outward K + current and the production of neurotoxic substances in microglial cells. Blockage of microglial K V 1.3 channel by either a specific K V 1.3 antagonist PAP or by a broad spectrum K channel blocker 4-AP significantly attenuated the potentiation of Meth on gp120-induced microglial neurotoxic activity. Further investigations revealed an involvement of caspase3/7 signaling in Meth-associated potentiation/synergy on gp120-induced microglial neurotoxic activity as demonstrated by the results that Meth/gp120-induced increase of caspase3/7 activity, and cleaved caspase 3 was inhibited by either a specific caspase 3 inhibitor or a specific K V 1.3 channel blocker.
Meth is one of the most commonly abused drugs among individuals infected with HIV-1 (Marquez et al., 2009) . Ample evidence indicate that Meth abuse increases the risk of HIV-1 infection (Buchacz et al., 2005; Gonzales et al., 2010; Mitchell et al., 2006) and exacerbates the cognitive deficits and neurodegenerative abnormalities in HIV-1-infected patients and animal models (Hoefer et al., 2015; Kesby et al., 2015a; Kesby et al., 2015b) . It has also been shown that HIV-1 infection and Meth abuse each alone can cause neuronal injury and cognitive impairments (Chana et al., 2006; Kaul et al., 2001; Larsen et al., 2002; Mattson et al., 2005; Xu et al., 2004) . Although HIV-1 does not infect neurons (Lindl et al., 2010) , neuronal injury is primarily thought to be mediated by the neurotoxins released from infected cells, mostly resident microglia (Gendelman and Meltzer, 1989; Meltzer and Gendelman, 1992; Xiong et al., 2000) . Among the neurotoxins is HIV-1 glycoprotein gp120. The neurotoxic effects of gp120 can be mediated either through direct or indirect mechanisms (Gonzalez-Scarano and Martin-Garcia, 2005; Kaul and Lipton, 2006b) . In terms of indirect mechanisms, gp120 has been shown to induce microglial activation and production of neurotoxic substances including, but not limited to, cytokines, chemokines, and nitric oxides (Albright et al., 2001; Lisi et al., 2012; Liu et al., 2012; Walsh et al., 2014) . Meth also acts on microglia and alters microglial secretory activity, exacerbating HIV-1/gp120-associated neurotoxicity (Loftis and Janowsky, 2014; Silverstein et al., 2012) . Our results revealed that microglia appear to be an intersecting target, as well as an effector, for the two. At a lower concentration, neither gp120 (0.1 nM) nor Meth (20 μM) triggered microglial neurotoxic activity. In contrast, Meth potentiated gp120-associated microglial neurotoxic activity when applied in combination. The observed potentiation suggests that Meth and gp120 may induce neural cell injury by acting on microglia, although Meth and gp120 have been reported to act on other types of central nervous system cells as well (Nair et al., 2009; Purohit et al., 2011; Shah et al., 2013; Shah et al., 2012) .
Despite mounting evidence that Meth abuse potentiates HIV-1 infection and HIV-1-associated neuropathology, limited studies have been carried out to explore the mechanisms underlying such a potentiation. It has been shown that Meth accelerates HIV infection and synergistically potentiates gp120-and Tat-associated neurotoxicity (Maragos et al., 2002; Nair et al., 2009; Nair and Samikkannu, 2012; Turchan et al., 2001) . Multiple mechanisms for Meth-induced potentiation have been proposed including upregulation of HIV-1 co- receptors CXCR4 and CCR5 expression (Nair and Saiyed, 2011; Nair et al., 2009) , interaction with NMDA receptors producing excitotoxic neural injury (Aksenov et al., 2012) , oxidative stress (Purohit et al., 2011; Shah et al., 2013) , and disruption of dopaminergic function (Aksenov et al., 2012; Purohit et al., 2011) and the blood-brain barrier (Mahajan et al., 2008) . In this study, we found that Meth and gp120 enhance microglial expression of K V 1.3 channel protein and outward K current leading to an increased microglial production of TNFα, IL-1β, and NO and resultant enhancement of microglial neurotoxic activity. To our knowledge, our results demonstrate for the first time that Meth and gp120 act in a converging way on microglial K V 1.3 to induce their comorbid effects through microglial activation and increased production of neurotoxins.
It has been demonstrated in animal models of neuroAIDS that gp120 protein may cause cognitive impairment, and Meth enhances such impairment (Henry et al., 2013; Hoefer et al., 2015; Kesby et al., 2015b) . A recent cross species study has also demonstrated that HIV-1 in humans and gp120 in animals impaired learning, and Meth exposure exacerbated HIV/gp120-associated neurocognitive deficits in both species (Kesby et al., 2015a) . These findings clearly indicate that the gp120 protein may contribute to HAND in humans. Considering the facts that HIV-1 infection becomes, in the era of cART, a chronic illness with very low levels of viral replication in microglia and both Meth and gp120 employed in this study were at sub-toxic doses, the results we observed that Meth potentiation of gp120 on microglial neurotoxic activity may reflect a pathophysiological condition in the brain of a HIV-1-infected Meth user under the cART regimen. Low levels of HIV/ gp120 in the brain may or may not induce microglia-associated neurotoxic activity. In the presence of Meth, however, the effect of HIV/gp120 on microglia could be exacerbated. This might explain why HAND remains prevalent even in the era of cART. Nevertheless, our results on Meth potentiation of gp120-associated microglial neurotoxic activity may have implications for HAND pathogenesis in the era of cART.
It is worth pointing out that the subtoxic concentrations of Meth and gp120, determined in a concentration-response study as shown in Fig. 1A , were employed in this study. The reasons for using subtoxic concentrations are: 1) to mimic the disease condition of HAND which becomes a chronic illness with very low levels of viral replication in the era of cART; and 2) to easily examine the potentate/synergistic effects of Meth and gp120 in an in vitro cell model of HAND pathogenesis. As both Meth and gp120 cause microglial cell damage at higher concentrations (Coelho-Santos et al., 2012; Xu et al., 2011) , it might be difficult to evaluate the effects of Meth potentiation of gp120-induced microglial neurotoxic activity. The use of subtoxic concentration of gp120 may also reflect the HAND pathogenesis in the cART era that lower levels of viral replication do not produce neural injury, but do cause neural injury in the presence of Meth, a potential mechanism underlying Meth exacerbation of HAND seen in HIV-1-infected patients. It is also worth pointing out that the conditioned media employed in this study was collected 24 h after addition of fresh neurobasal media (see methods). Although this procedure prevents the direct action of Meth and gp120 on neuronal cells, it may remove all the proinflammatory substances released by microglia during the first 24 h in culture and contributes to the low (subtoxic) effects of Meth (20 μM) or gp120 (0.1 nM). Thus, the "subtoxic" concentrations of Meth and gp120 employed in the present study are only applicable for an experimental condition.
In summary, the present study demonstrated that Meth potentiates gp120-induced microglial neurotoxic activity via activation of voltagegated K channel K V 1.3 and caspase 3/7 signaling. Under experimental conditions, Meth or gp120 each alone at a low concentration had no apparent effect on triggering microglial neurotoxic activity. When applied in combination, however, Meth significantly potentiated gp120-induced microglial neurotoxicity. The Meth potentiation of gp120-associated microglial neurotoxic activity was blocked by specific K V 1.3 channel blockers, suggesting an involvement of K V 1.3 in Meth-mediated potentiation. Considering the scenarios of HIV-1 brain infection plus Meth abuse in the era of cART, when the levels of viral replication are low and long-term use of Meth, the observed Meth potentiation of gp120-associated microglial neurotoxic activity at subtoxic concentrations may represent a potential mechanism for HAND pathogenesis in the era of cART.
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